AlTi Global Inc. Buys New Position in Kenvue Inc. $KVUE

AlTi Global Inc. acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,450 shares of the company’s stock, valued at approximately $219,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the 1st quarter worth about $30,000. Trust Co. of Vermont grew its holdings in shares of Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the period. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue during the 1st quarter worth about $36,000. Truvestments Capital LLC purchased a new stake in shares of Kenvue during the 1st quarter worth about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on KVUE shares. Evercore ISI decreased their target price on Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a report on Tuesday, September 23rd. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research report on Friday, September 26th. JPMorgan Chase & Co. lowered their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.75.

Kenvue Stock Performance

Kenvue stock opened at $15.00 on Friday. The stock has a market cap of $28.78 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 2.16 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average of $17.91 and a 200-day moving average of $20.79. Kenvue Inc. has a 52 week low of $14.05 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business’s revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.5%. Kenvue’s dividend payout ratio (DPR) is currently 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.